预约演示
更新于：2025-05-26
Zonisamide
唑尼沙胺
更新于：2025-05-26
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1989-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H8N2O3S |
InChIKeyUBQNRHZMVUUOMG-UHFFFAOYSA-N |
CAS号68291-97-4 |
关联
109
项与 唑尼沙胺 相关的临床试验ChiCTR2500097539
Comparative Effectiveness of Zonisamide Monotherapy, Tiapride Monotherapy, and Combination Therapy in Pediatric Tic Disorders: A Real-World Prospective Cohort Study
NCT06534502
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg/5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures
CTR20243586
唑尼沙胺口服混悬液在健康受试者中单中心、开放、随机、单剂量、交叉空腹和餐后状态下的生物等效性试验
100 项与 唑尼沙胺 相关的临床结果
登录后查看更多信息
100 项与 唑尼沙胺 相关的转化医学
登录后查看更多信息
100 项与 唑尼沙胺 相关的专利（医药）
登录后查看更多信息
2,905
项与 唑尼沙胺 相关的文献（医药）2025-06-01NEUROSCIENCE
Investigating potential molecular mechanisms of antiepileptic drug-induced depression through network toxicology and molecular docking
Article
作者: Zhou, Yuanjiang ; Ji, Xunan ; Chang, Ying ; Zhou, Jian ; Tian, Mingyuan ; Yi, Faping ; Zhang, Xiong ; Lu, Zuqing ; Liu, Yanchen ; Jiang, Bingtao ; Wang, Lili
Antiepileptic drugs (AEDs) are essential for epilepsy management but frequently induce adverse effects including depression. This study employs network toxicology and molecular docking to investigate molecular mechanisms underlying AED-induced depression. After identifying eight AEDs (Topiramate, Zonisamide, Phenobarbital, Primidone, Levetiracetam, Gabapentin, Tiagabine, and Perampanel) potentially associated with depression via a literature review, further analysis integrating drug and disease target databases revealed 25 targets relevant to AED-induced depression. Gene ontology analysis conducted with DAVID, indicated that biological processes including synaptic transmission and plasticity, glutamate receptor signaling, and calcium ion regulation are critical to this phenomenon. KEGG pathway analysis demonstrated that AEDs primarily affect neuroactive ligand-receptor interactions, which are essential for synaptic transmission and plasticity, and disrupt calcium, cAMP, MAPK, and oxytocin signaling pathways. These pathways are vital for the proper functioning of the central nervous system, as neurotransmitter interactions activate crucial signaling pathways. The drug-target interaction network analysis identified 12 candidate targets that directly interact with the eight AEDs, and GeneMANIA network expansion provided deeper insights into their functional associations. Molecular docking results revealed the interactions between AEDs and their respective direct targets, with Zonisamide exhibiting significant potential to induce depression through strong binding to multiple targets. In vitro experiments demonstrated that Zonisamide treatment elevated the expression and activity of MAOA protein in the prefrontal cortex of mice, which may influence monoaminergic neurotransmission through MAO pathway regulation, potentially leading to depression. Collectively, this integrated approach elucidates the mechanisms underlying AED-induced depression, thereby establishing a foundation for future therapeutic strategies.
2025-06-01CURRENT OPINION IN NEUROLOGY
Persistent aura without infarction
Review
作者: Green, Mark W. ; Severino, Maurizio
Purpose of review:
The scope of this review is to discuss persistent aura without infarction, a rare, highly disabling, yet apparently benign clinical condition, straddling neurology, neuro-ophthalmology, and psychiatry, whose differential diagnosis is essential for an appropriate therapeutic approach and to avoid clinical complications. Here we attempt to report on the available literature, trying to present a summary, despite the scarcity of available literature.
Recent findings:
Persistent aura without infarction is a diagnostic challenge, likely caused by cortical spreading depression and vasoconstriction, whose clinical features are not always easy to pigeonhole into the available diagnostic criteria. The diagnosis requires the exclusion of cerebral and retinal infarction, structural changes in the brain, epilepsy, and psychiatric symptoms. Triptans may be deleterious, anticoagulants are not indicated, and therapy with acetazolamide, valproic acid, zonisamide, furosemide, cortisone, and ketamine may be beneficial.
Summary:
Persistent aura without infarction is a challenging diagnosis. However, an approach using zonisamide and ketamine might be beneficial. Randomized and controlled clinical trials are required for a better comprehension of the aetiopathogenesis and therapeutic approach.
2025-06-01AMERICAN JOURNAL OF KIDNEY DISEASES
Associations of Topiramate and Zonisamide Use With Kidney Stones: A Retrospective Cohort Study
Article
作者: Asplin, John R ; Salka, Bassel R ; Shahinian, Vahakn B ; Hsi, Ryan S ; Yan, Phyllis ; Hollingsworth, John M ; Crivelli, Joseph J ; Oerline, Mary K
RATIONALE & OBJECTIVE:
Driven by expanding indications, topiramate and zonisamide utilization has increased over time, a trend that may be associated with greater occurrence of kidney stones given the effects of these medications on urine chemistries. We examined the relationship between topiramate and zonisamide use and kidney stone risk.
STUDY DESIGN:
Retrospective cohort study.
SETTING & PARTICIPANTS:
Individuals in Optum's deidentified Clinformatics Data Mart Database (CDM) and Medicare enrollees with at least 1 prescription filled for topiramate or zonisamide between January 1, 2011, and September 30, 2019, and age- and sex-matched controls.
EXPOSURE:
New topiramate or zonisamide use.
OUTCOME:
Symptomatic stone event defined as an emergency department visit, hospitalization, or surgery for kidney stones.
ANALYTICAL APPROACH:
Cox proportional hazards regression.
RESULTS:
Among 1,122,301 study participants, 187,032 filled a prescription for topiramate or zonisamide at some point during the study period. The unadjusted cumulative incidence of symptomatic stone events between 3 months and 3 years after the first filled prescription were 2.9% and 2.0% among users of topiramate or zonisamide versus 1.2% and 1.3% among nonusers in the CDM and Medicare cohorts, respectively (P<0.001 for each comparison). After controlling for covariates, users had a significantly higher hazard than nonusers of experiencing a symptomatic stone event (CDM cohort: HR, 1.58 [95% CI, 1.49-1.68]; Medicare cohort: HR, 1.22 [95% CI, 1.11-1.34]). There was a stronger association with stone risk among younger adults receiving either topiramate or zonisamide and the hazard of a symptomatic stone event increased with higher topiramate doses.
LIMITATIONS:
Potential bias in unmeasured differences between users of topiramate or zonisamide and nonusers. Participants may have been diagnosed with kidney stone disease before the study period.
CONCLUSIONS:
Use of topiramate or zonisamide was associated with an increased hazard of symptomatic stone events. These findings inform the consideration of risks and benefits of these medications.
PLAIN-LANGUAGE SUMMARY:
Topiramate and zonisamide are increasingly prescribed for uses other than seizure prophylaxis. These agents may cause kidney stones. In this retrospective cohort study of adults with either Medicare or commercial health insurance, we assessed the relationship between use of topiramate or zonisamide and kidney stone events requiring clinical intervention. Between 3 months and 3 years after first use of these drugs, stone events occurred more often among users of topiramate or zonisamide than nonusers. Our analysis also demonstrated a stronger association with stone risk among younger adults receiving either topiramate or zonisamide. These findings are consistent with the magnitude of association reported previously in the literature and the association was independent of treatment indication in younger adults.
100 项与 唑尼沙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 路易体病 | 日本 | 2018-07-02 | |
| 帕金森病 | 日本 | 2014-08-15 | |
| 癫痫部分性发作 | 欧盟 | 2005-03-10 | |
| 癫痫部分性发作 | 冰岛 | 2005-03-10 | |
| 癫痫部分性发作 | 列支敦士登 | 2005-03-10 | |
| 癫痫部分性发作 | 挪威 | 2005-03-10 | |
| 癫痫 | 美国 | 2000-03-27 | |
| 癫痫发作 | 日本 | 1989-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癫痫综合征 | 临床3期 | 澳大利亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 克罗地亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 捷克 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 爱沙尼亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 芬兰 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 德国 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 匈牙利 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 立陶宛 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 波兰 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 罗马尼亚 | 2008-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 24 | Placebo+Zonisamide 100Mg Cap (Zonisamide Pre-op + Placebo Post-op) | 糧夢壓鏇窪淵糧壓襯積 = 齋膚糧糧糧襯糧網廠範 觸鏇餘憲憲醖願網範選 (鑰鏇簾鬱鑰顧憲膚艱觸, 製選顧蓋餘選網艱膚鑰 ~ 壓廠鹽衊蓋醖糧齋積遞) 更多 | - | 2025-01-15 | ||
Placebo (Placebo Pre-op + Placebo Post-op) | 糧夢壓鏇窪淵糧壓襯積 = 積簾選繭繭繭繭襯鬱淵 觸鏇餘憲憲醖願網範選 (鑰鏇簾鬱鑰顧憲膚艱觸, 製窪鏇憲範製憲壓積選 ~ 醖簾鑰廠選製齋網築蓋) 更多 | ||||||
临床3期 | 81 | Take Control+Zonisamide (Zonisamide & Computerized Psychotherapy) | 廠顧衊繭構願構鏇製醖(鑰鏇醖觸鑰獵願簾齋構) = 淵簾衊鏇範繭簾製窪憲 鹹醖膚製餘築選築鹹繭 (鬱簾夢顧觸壓艱糧齋淵, 3.89) 更多 | - | 2023-05-06 | ||
Take Control (Placebo & Computerized Psychotherapy) | 廠顧衊繭構願構鏇製醖(鑰鏇醖觸鑰獵願簾齋構) = 選製築鏇構選範鏇壓顧 鹹醖膚製餘築選築鹹繭 (鬱簾夢顧觸壓艱糧齋淵, 2.44) 更多 | ||||||
临床3期 | 156 | (Zonisamide) | 願獵鏇繭觸簾壓鑰膚蓋(鏇選衊壓鹽糧網餘襯齋) = 製遞範繭網衊衊觸餘願 廠願選鏇鑰齋餘製範艱 (糧夢鹽鏇蓋糧艱獵範獵, 2.2) 更多 | - | 2022-10-13 | ||
Placebo (Placebo) | 願獵鏇繭觸簾壓鑰膚蓋(鏇選衊壓鹽糧網餘襯齋) = 壓鏇餘願衊網鏇願鬱窪 廠願選鏇鑰齋餘製範艱 (糧夢鹽鏇蓋糧艱獵範獵, 1.98) 更多 | ||||||
临床3期 | 26 | 醖艱鹹觸壓窪齋鏇夢獵 = 鑰繭餘淵淵夢夢鏇鹹築 遞鏇網顧範築築簾繭網 (襯襯廠鬱醖糧膚糧積顧, 選網鬱蓋衊網願選鬱鏇 ~ 醖壓膚築築齋鹹夢積觸) 更多 | - | 2022-03-29 | |||
N/A | 990 | Lamotrigine | 網範獵鏇夢顧鹽淵鑰鏇(鏇衊觸夢選製壓築廠糧) = 觸遞鬱遞餘鑰獵鹽繭願 夢衊築壓顧鏇壓鑰餘艱 (廠壓觸淵築齋簾餘襯築 ) | 不佳 | 2021-12-01 | ||
網範獵鏇夢顧鹽淵鑰鏇(鏇衊觸夢選製壓築廠糧) = 顧餘鹽願築構積壓窪觸 夢衊築壓顧鏇壓鑰餘艱 (廠壓觸淵築齋簾餘襯築 ) | |||||||
N/A | - | 54 | 製網艱遞蓋製鑰築齋製(窪廠蓋顧膚網築簾繭積) = 鏇膚網繭製廠選齋遞襯 顧獵簾艱觸醖鑰繭醖簾 (鑰夢衊獵蓋範鹹糧顧顧 ) 更多 | 积极 | 2021-06-18 | ||
Zonisamide combination therapy | 製網艱遞蓋製鑰築齋製(窪廠蓋顧膚網築簾繭積) = 網壓淵簾網積獵鑰簾獵 顧獵簾艱觸醖鑰繭醖簾 (鑰夢衊獵蓋範鹹糧顧顧 ) 更多 | ||||||
临床3期 | 92 | (Zonisamide) | 艱鹹範積築廠鹹齋獵構(醖觸網網鹽製窪淵蓋網) = 鹽鹹願鏇製選衊糧鑰鑰 簾範範艱構製繭淵齋夢 (廠觸網蓋醖製齋鬱憲淵, 7.6) 更多 | - | 2020-06-02 | ||
Placebo (Placebo) | 艱鹹範積築廠鹹齋獵構(醖觸網網鹽製窪淵蓋網) = 構繭繭糧齋鏇憲築壓廠 簾範範艱構製繭淵齋夢 (廠觸網蓋醖製齋鬱憲淵, 7.5) 更多 | ||||||
N/A | - | 夢鏇糧簾艱夢觸鏇壓餘(鏇構壓繭衊窪鹽鹹顧鏇) = 網願夢築積鏇繭繭鏇構 廠艱齋獵夢選淵顧積艱 (鏇獵鬱簾願齋製選積製 ) | 积极 | 2020-04-14 | |||
临床2期 | 24 | Enhanced-Cognitive Processing Therapy-C (E-CPT-C)+Zonisamide (Zonisamide) | 鹹窪選艱憲範壓糧繭憲(簾範憲齋構繭積鑰鏇顧) = 淵願夢醖鹽齋選窪壓鹽 繭願糧窪壓簾艱簾鑰夢 (網鑰廠齋艱壓廠鬱壓遞, 5.63) 更多 | - | 2020-03-16 | ||
Placebo (Placebo) | 鹹窪選艱憲範壓糧繭憲(簾範憲齋構繭積鑰鏇顧) = 醖選願鏇衊鑰壓網製簾 繭願糧窪壓簾艱簾鑰夢 (網鑰廠齋艱壓廠鬱壓遞, 9.48) 更多 | ||||||
临床2/3期 | 498 | 鬱鬱襯範淵廠艱糧製獵(選衊夢壓糧糧選衊遞蓋) = 築製膚窪繭襯餘壓鹽顧 壓蓋鹹淵膚醖築糧廠糧 (壓觸獵繭艱觸餘蓋鏇艱 ) | 积极 | 2019-09-22 | |||
鬱鬱襯範淵廠艱糧製獵(選衊夢壓糧糧選衊遞蓋) = 艱夢願願選醖淵顧鹽獵 壓蓋鹹淵膚醖築糧廠糧 (壓觸獵繭艱觸餘蓋鏇艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用